Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire ZETA-1 Topline Results Conference Call

Jan 25, 2023 • 4:30pm EST

Planet MicroCap Conference

Dec 8, 2022 • 11:30am - 12:00pm EST